文献速递脑血管病外科神经重症

克拉生坦治疗动脉瘤性蛛网膜下腔出血后的疗效与安全性:一项更新的Meta分析

Efficacy and Safety of Clazosentan After Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis.
PubMed 文献 · Neurosurgery · 2023-07-18

该Meta分析纳入6项研究共7个随机对照试验、2778例患者,比较克拉生坦与安慰剂治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的效果。克拉生坦降低血管痉挛相关迟发性脑缺血(RR 0.56,95%CI 0.38-0.81)和迟发性缺血性神经功能缺损(RR 0.63,95%CI 0.50-0.80),也降低血管造影性血管痉挛(RR 0.54,95%CI 0.47-0.61),但功能结局(RR 0.99,95%CI 0.79-1.24)和死亡(RR 1.03,95%CI 0.71-1.49)无变化,不良事件增加(RR 1.54,95%CI 1.35-1.76)。

要点

  • 克拉生坦降低血管痉挛相关迟发性脑缺血(RR 0.56,95%CI 0.38-0.81)。
  • 克拉生坦未改善功能结局(RR 0.99,95%CI 0.79-1.24)或死亡(RR 1.03,95%CI 0.71-1.49)。
  • 克拉生坦增加不良事件(RR 1.54,95%CI 1.35-1.76)。

核心结论

  • 克拉生坦降低血管痉挛相关迟发性脑缺血和血管造影性血管痉挛,但未改善功能结局或死亡率,且不良事件增加。

研究设计与样本

  • 系统检索数据库纳入直接比较克拉生坦与安慰剂治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的随机对照试验,共纳入6项研究包含7个临床试验、2778例患者,使用Cochrane RoB-2工具评估研究质量。

主要发现

  • 克拉生坦降低血管痉挛相关迟发性脑缺血(RR 0.56,95%CI 0.38-0.81)和迟发性缺血性神经功能缺损(RR 0.63,95%CI 0.50-0.80)。
  • 克拉生坦降低血管造影性血管痉挛(RR 0.54,95%CI 0.47-0.61)。
  • 功能结局(良好格拉斯哥结局量表,RR 0.99,95%CI 0.79-1.24)和死亡(RR 1.03,95%CI 0.71-1.49)无变化。
  • 克拉生坦增加不良事件(RR 1.54,95%CI 1.35-1.76)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Clazosentan has been studied to treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH).This meta-analysis of randomized controlled trials updates the current knowledge regarding the efficacy and safety of clazosentan compared with placebo after aSAH. METHODS: Databases were systematically searched for randomized controlled trials directly comparing the use of clazosentan and placebo for the treatment of cerebral vasospasm after aSAH. Additional eligibility criteria were the report of any of the outcomes of interest (vasospasm, morbidity, functional outcome, or mortality). The primary outcome was vasospasm-related delayed cerebral ischemia (DCI). The analyses were stratified by clazosentan dosage (low or high dose) and aneurysm treatment modality (clipping or coiling). The Cochrane RoB-2 tool was used for studies quality assessment. RESULTS: Six studies comprising 7 clinical trials were included, involving 2778 patients. Clazosentan decreased the risk of vasospasm-related DCI (risk ratio [RR] 0.56, 95% CI 0.38-0.81) and delayed ischemic neurological deficit (RR 0.63, 95% 0.50-0.80). Angiographic vasospasm (RR 0.54, 95% CI 0.47-0.61) was also decreased. Functional outcomes (favorable Glasgow Outcome Scale, RR 0.99, 95% CI 0.79-1.24) and death (RR 1.03, 95% CI 0.71-1.49) did not change. Meanwhile, adverse events were increased by clazosentan (RR 1.54, 95% CI 1.35-1.76). CONCLUSION: Clazosentan decreased vasospasm-related DCI and angiographic vasospasm but did not improve functional outcomes or mortality. Adverse events were increased by clazosentan.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Pontes JPM, Santos MDC, Gibram FC, et al. Efficacy and Safety of Clazosentan After Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis. Neurosurgery. 2023. PMID: 37462365. doi:10.1227/neu.0000000000002601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。